Abstract
Although patients taking direct oral anticoagulants (DOACs) do not require routine coagulation monitoring, anti-factor Xa activity (AXA) values in patients on apixaban, edoxaban and rivaroxaban therapy are still not clear. 158 patients taking DOACs (apixaban; N=45, edoxaban; N=87 and rivaroxaban; N
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
